How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

681 results for

Sibutramine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

121. What weight loss treatment options do geriatric patients with overweight and obesity want to consider? Full Text available with Trip Pro

What weight loss treatment options do geriatric patients with overweight and obesity want to consider? Since the 1990s, a number of weight loss medications have been removed from the USA and or European market because of adverse events associated with these medications. These medications include fenfluramine (heart valve thickening), sibutramine (cardiovascular risk) and rimonabant (depression). This history may affect a patient's desire to consider weight loss medications as an option

2016 Obesity science & practice

122. Can social media data lead to earlier detection of drug‐related adverse events? Full Text available with Trip Pro

Can social media data lead to earlier detection of drug‐related adverse events? To compare the patient characteristics and the inter-temporal reporting patterns of adverse events (AEs) for atorvastatin (Lipitor® ) and sibutramine (Meridia® ) in social media (AskaPatient.com) versus the FDA Adverse Event Reporting System (FAERS).We identified clinically important AEs associated with atorvastatin (muscle pain) and sibutramine (cardiovascular AEs), compared their patterns in social media (...) postings versus FAERS and used Granger causality tests to assess whether social media postings were useful in forecasting FAERS reports.We analyzed 998 and 270 social media postings between 2001 and 2014, 69 003 and 7383 FAERS reports between 1997 and 2014 for atorvastatin and sibutramine, respectively. Social media reporters were younger (atorvastatin: 53.9 vs. 64.0 years, p < 0.001; sibutramine: 36.8 vs. 43.8 years, p < 0.001). Social media reviews contained fewer serious AEs (atorvastatin, pain: 2.5

2016 Pharmacoepidemiology and drug safety

123. Preparation of a β-Cyclodextrin-Based Open-Tubular Capillary Electrochromatography Column and Application for Enantioseparations of Ten Basic Drugs Full Text available with Trip Pro

concentration and background electrolyte pH on the chiral separation were investigated. With the developed separation mode, all the enantiomers (except for venlafaxine) were baseline separated in resolutions of 4.49, 1.68, 1.88, 1.57, 2.52, 2.33, 3.24, 1.63 and 3.90 for zopiclone, chlorphenamine maleate, brompheniramine maleate, dioxopromethazine hydrochloride, carvedilol, homatropine hydrobromide, homatropine methylbromide, venlafaxine, sibutramine hydrochloride and terbutaline sulfate, respectively

2016 PloS one

124. Ultrasound of the Knee in Obese Patients With Knee Osteoarthritis; Weight Maintenance

the last 3 months) Current or history of treatment with medications that may cause significant weight gain for at least 3 months before this trial Current use or use within three months before this trial of GLP-1 receptor agonist, pramlintide, sibutramine, orlistat, zonisamide, topiramate, or phentermine Type 1 diabetes Type 2 diabetes treated with glucose-lowering drugs other than metformin Alloplasty in target knee joint (see section 6.3) End stage disease in target knee joint (Kellgren-Lawrence

2016 Clinical Trials

125. Ultrasound of the Knee in Obese Patients With Knee Osteoarthritis; Weight Loss

programme (or within the last 3 months) Current or history of treatment with medications that may cause significant weight gain for at least 3 months before this trial Current use or use within three months before this trial of GLP-1 receptor agonist, pramlintide, sibutramine, orlistat, zonisamide, topiramate, or phentermine Type 1 diabetes Type 2 diabetes treated with glucose-lowering drugs other than metformin Alloplasty in target knee joint (see section 6.3) End stage disease in target knee joint

2016 Clinical Trials

126. Ultrasound Assessment of the Carotid Intimal Medial Thickness in Obese Subjects; Weight Loss

programme (or within the last 3 months) Current or history of treatment with medications that may cause significant weight gain for at least 3 months before this trial Current use or use within three months before this trial of GLP-1 receptor agonist, pramlintide, sibutramine, orlistat, zonisamide, topiramate, or phentermine Type 1 diabetes Type 2 diabetes treated with glucose-lowering drugs other than metformin Alloplasty in target knee joint (see section 6.3) End stage disease in target knee joint

2016 Clinical Trials

127. Effects of Inulin and Arabinoxylan on Satiety, Energy/Food Intake and Changes in the Human Gut Microbiota

/d dietary fibre consumption as well as those with food allergies Gastrointestinal procedure or surgery in the past three months. Gastrointestinal disorders: celiac disease, Intestinal Bowel Disease (IBD), irritable bowel syndrome (IBS), chronic constipation, diverticulitis or a history of chronic constipation, diarrhoea, or other chronic gastrointestinal complaints Disorders of swallowing, severe dysphagia to food or pills. Appetite modulator drugs: orlistat, sibutramine, rimonabant. Mood

2016 Clinical Trials

128. Changes in Skin Autoflouresence Following Weight Loss and Maintenance Using Liraglutide in Knee Osteoarthritis

within three months before this trial of GLP-1 receptor agonist, pramlintide, sibutramine, orlistat, zonisamide, topiramate, or phentermine Type 1 diabetes Type 2 diabetes treated with glucose-lowering drugs other than metformin Alloplasty in target knee joint (see section 6.3) End stage disease in target knee joint (Kellgren-Lawrence grade 4) Immuno-inflammatory disease Chronic wide-spread pain Pregnancy or insufficient anti-conception therapy for female fertile patients Breast-feeding Estimated

2016 Clinical Trials

129. Liraglutide 3 mg for Knee Osteoarthritis

, in an organised weight loss programme (or within the last 3 months) Current or history of treatment with medications that may cause significant weight gain for at least 3 months before this trial Current use or use within three months before this trial of GLP-1 receptor agonist, pramlintide, sibutramine, orlistat, zonisamide, topiramate, or phentermine Type 1 diabetes Type 2 diabetes treated with glucose-lowering drugs other than metformin Alloplasty in target knee joint (see section 6.3) End stage disease

2016 Clinical Trials

130. Does Treating Anxiety Symptoms With ACT Improve Vascular Inflammation and Function?

, Aloprim®). Taking steroids or biologics: corticosteroids (prednisone); methotrexate, infliximib (Remicade®), etaneracept (Enbrel®); anakinra (Kineret®). Vulnerable populations (prisoners, etc.) will not be eligible to participate in this study. Current alcohol abuse. On weight loss drugs (i.e. orilistat (Xenical®), sibutramine (Meridia®), phenylpropanol-amine (Acutrim®)), or similar over-the-counter medications within 3 months of screening. Any condition that, in the view of the PI or Co-I, places

2016 Clinical Trials

131. Catgut Implantation at Acupoints for the Treatment of Simple Obesity

interventions in controlled trials of acupuncture: the STRICTA recommendations. J Altern Complement Med. 2002;8:85 - 9. Ralph JL, Von Ah D, Scheett AJ, Hoverson BS, Anderson CM. Diet assessment methods: a guide for oncology nurses. Clin J Oncol Nurs. 2011;15:E114 - 21. James WP, Astrup A, Finer N, Hilsted J, Kopelman P, Rössner S, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance Lancet

2016 Clinical Trials

132. Effectiveness of Changing Dietary Fat on Weight Loss

of 20-60 years of age. Body Mass Index (BMI) 27.0 -35.0 kg/m2. Not currently taking a prescription medication for weight loss (e.g. orlistat (Xenical®), sibutramine (Meridia®) or phentermine etc.) If subject is willing to discontinue prescription medication(s) immediately and willing to refrain from taking medication(s) for duration of study, he/she may be enrolled after a four-week washout period. Not currently taking any over-the-counter weight loss supplement(s) or appetite suppressants

2016 Clinical Trials

133. The Effect of Hypocaloric Diet Associated With tDCS on Weight Loss and Metabolic Profile

or blood transfusion in the past 8 weeks. Treatment with any oral antidiabetic drugs and / or herbal preparations or medications that do not require a prescription and can affect glycemic control within 12 weeks prior to screening. Chronic treatment with oral or parenteral corticosteroids (> 7 consecutive days of treatment) within 4 weeks prior to screening. Treatment with weight loss agents (e.g., orlistat, sibutramine, topiramate, bupropion) in the last 12 weeks prior to screening. Treatment

2016 Clinical Trials

134. Influence of Liraglutide, a GLP-1 Receptor Agonist, on Brown Adipose Tissue (BAT) Activity in Humans

of treatment, i.e. 7−10 days), tricyclic antidepressants, atypical antipsychotic and mood stabilizers (e.g. imipramine, amitriptyline, mirtazapine, paroxetine, phenelzine, chlorpromazine, thioridazine, clozapine, olanzapine, valproic acid and its derivatives, and lithium); Current participation (or within the last 3 months) in an organized weight reduction program Currently or previous using within 3 months before screening of pramlintide, sibutramine, orlistat, topiramate, or metformin (either

2016 Clinical Trials

135. The Assessment of the Effect of Vitamin D Supplementation on Inflammatory and Endothelial Factors in the Patients With Type 2 Diabetes .

- or hyperthyroidism, treatment with orlistat or sibutramine for weight loss, pregnancy and lactation, treatment with insulin or Thiazolidinediones, Smokers,sever change in regular diet and life style,change in type and dosage of regular medication (s) Contacts and Locations Go to No Contacts or Locations Provided More Information Go to Layout table for additonal information Responsible Party: Tehran University of Medical Sciences ClinicalTrials.gov Identifier: Other Study ID Numbers: 32615 First Posted: January 2

2016 Clinical Trials

136. Effects of Combined Dapagliflozin and Exenatide Versus Dapagliflozin and Placebo on Ectopic Lipids in Patients With Uncontrolled Type 2 Diabetes Mellitus.

absolute or relative contraindication for the conduct of an MRI investigation, such as cardiac pacemakers, ferromagnetic haemostatic clips in the central nervous system, metallic splinters in the eye, ferromagnetic or electronically operated active devices like automatic cardioverter defibrillators,cochlear implants, insulin pumps and nerve stimulators, prosthetic heart valves etc. History of bariatric surgery Treatment with anti-obesity drugs (e.g. sibutramine, orlistat) 3 months prior to informed

2016 Clinical Trials

137. Relation between weight loss and causes of death in patients with cardiovascular disease: finding from the SCOUT trial. (Abstract)

Relation between weight loss and causes of death in patients with cardiovascular disease: finding from the SCOUT trial. Obesity is associated with an increased incidence of mortality. The Sibutramine Cardiovascular Outcomes (SCOUT) trial can provide the first evidence of the effect of intentional weight loss on mortality in an obese population at high risk.SCOUT was a randomized, double-blind, placebo-controlled trial testing sibutramine vs. placebo. Eligibility for the trial required both men (...) event.The relationship between weight loss and mortality (all-cause, cardiovascular, and noncardiovascular) was investigated with Cox regression models.The main study showed that all-cause mortality was not different in patients allocated to sibutramine or placebo. This ancillary analysis demonstrates that there is a general trend showing higher mortality in patients with the greatest weight loss (weight reduction >10 kg) and in those with increasing weight (>1 kg). If integrated weight loss (area under

2016 Journal of cardiovascular medicine (Hagerstown, Md.) Controlled trial quality: predicted high

138. Long-term randomized clinical trials of pharmacological treatment of obesity: systematic review

search terms were reported. Study selection Randomised controlled trials that evaluated the efficacy of treatments with orlistat, sibutramine and rimonabant, that followed participants for at least 24 months and that measured weight loss were eligible for inclusion. Participants with hypertension (sibutramine studies) and neuro-psychiatric diseases (rimonabant studies) were excluded. Most studies included clinically obese white women (without cardiac, renal, liver and gastrointestinal illnesses (...) to intervention. Results of the review Eleven RCTs (n=11,710, range 61 to 3,305 participants) met the inclusion criteria. Seven studies assessed orlistat and two studies each assessed sibutramine and rimonabant. One study scored 5, three studies scored 4, five studies scored 3 and one study scored 2 on the Jadad scale (score for one study not reported). Eight studies were double blind. Nine studies were analysed by intention to treat (ITT). Baseline differences were reported to be significant. Withdrawal

2010 DARE.

140. Study on health hazards through medicines purchased on the Internet: a cross-sectional investigation of the quality of anti-obesity medicines containing crude drugs as active ingredients. Full Text available with Trip Pro

and not medicines. Even though we did not analyze the constituents of all crude drugs, we found some active ingredients in the items. Sibutramine was detected in items confirmed to be supplements, including those containing Poria sclerotium and Ophiopogonis tuber. Each capsule contained ≈ 12 mg of sibutramine, which is the daily dose for anti-obesity medicines. Sibutramine is not approved for use in Japan and its sale has been suspended in Europe and the USA owing to serious adverse effects on the circulatory

2015 BMC Complementary and Alternative Medicine

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>